Phase I trial in healthy volunteers of AG 014 bacteria for oral administration of certolizumab as a therapy for inflammatory bowel disease.

Trial Profile

Phase I trial in healthy volunteers of AG 014 bacteria for oral administration of certolizumab as a therapy for inflammatory bowel disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs AG 014 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ActoGeniX
  • Most Recent Events

    • 29 Oct 2014 New trial record
    • 15 Oct 2014 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top